This multi-peptide blend may offer broader regenerative support compared to single-peptide approaches
Oral semaglutide at 25 mg appears to match the results of injectable Wegovy at 2.4 mg in the OASIS 4 trial, but real-world switching data are limited
The G protein-coupled receptor of GLP-1 (GLP-1R) originally identified in islet -cells is widely expressed in extrapancreatic tissues as well including the lungs, kidney, brain, the enteric and peripheral nervous system, lymphocytes, smooth muscle cells (SMCs), and atrial cardiomyocytes [32] The specific identity of GLP-1 receptor-positive (GLP-1R+) cells in the heart remains uncertain
Type II Diabetes Patients: NAION risks increased from 1.8% in non-semaglutide users to 8.9% in semaglutide users , representing a 710% increased absolute risk
Chang Y, Huang Z, Hou F, Liu Y, Wang L, Wang Z, et al